People In Brief
This article was originally published in The Gray Sheet
Executive Summary
J&J CFO to retire: Johnson & Johnson CFO Robert Darretta announces plans to retire early next year, ending his 38-year tenure with the firm. Daretta is credited with guiding capital-efficient, profitable growth throughout each of the J&J divisions, the Oct. 6 announcement says. As vice chairman of the board since 2004, Darretta has assisted in the development of new procurement practices. Current VP-Group Finance Dominic Caruso will take over as CFO, effective Jan. 1. Caruso joined J&J in 1999 through its acquisition of Centocor...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.